Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1: Anta Sports Acquisition of Puma - Anta Sports has signed an agreement to acquire 29.06% of Puma's shares, totaling €1.5055 billion (approximately ¥12.2776 billion), making it the largest shareholder of Puma [1][16][19] - The acquisition aims to collaborate with the Puma team to reshape the brand strategy, enhance its value, and fully unlock Puma's growth potential [2][17][19] - Anta believes that Puma has strong brand value and genetic traits that are rare and cannot be measured solely by short-term profitability or current acquisition prices [2][17] Group 2: Market Potential and Strategic Support - The Chinese market is one of the largest sports goods markets globally, yet Puma's revenue from China accounts for less than 7%, indicating significant development potential [2][17] - Anta's insights into Chinese consumers and its comprehensive operational capabilities are expected to provide strong strategic support for Puma's growth in China, aiming for growth above the industry average [2][17] - Anta has demonstrated strong organizational capabilities over the past decade, successfully growing brands like FILA and Salomon from obscurity to billion-dollar brands [2][17] Group 3: Operational Independence and Collaboration - Despite becoming the largest shareholder, Anta is not a controlling shareholder and recognizes the importance of maintaining operational independence while fostering deep collaboration with Puma [3][18] - The success of the partnership relies on building deep trust and forming a strong alliance, with Anta planning to appoint suitable representatives to work alongside Puma's management team [3][18] Group 4: Financial Performance and Growth Outlook - Anta's acquisition is expected to enhance its financial performance, with a focus on leveraging its strengths to support Puma's recovery and growth in the Chinese market [2][17] - The company has a clear understanding of the operational challenges ahead and has developed internal plans to address Puma's current losses and product line issues [2][17]

Core Insights - The report emphasizes the continuous growth potential in the innovative pharmaceutical sector, particularly focusing on CXO, innovative drugs, and high-value consumables as key investment areas for 2025 [5][10][11] Performance Forecast - As of February 1, 2025, 261 pharmaceutical companies listed on A-shares have released performance forecasts, with 129 companies expected to be profitable. Among these, 85 companies anticipate profit growth, while 44 expect declines, and 25 are projected to turn losses into profits [6][7] - The report predicts the following profit growth rates for 28 pharmaceutical companies in 2025: - 2 companies with growth rates of 40% or more: SaiFen Technology and JiuZhou Pharmaceutical - 8 companies with growth rates between 20% and 40%: ZuoLi Pharmaceutical, AoRuiTe, HaoYuan Pharmaceutical, BiDe Pharmaceutical, DaSanLin, WoWu Biological, TeBao Biological, and HengRui Pharmaceutical - 10 companies with growth rates between 10% and 20%: BaiYunShan, LingRui Pharmaceutical, KaiLaiYing, PuRuiSi, YaoKang Biological, XiangSheng Medical, KeFu Medical, YiFeng Pharmacy, XinLiTai, and LanXiao Technology - 7 companies with growth rates between 0% and 10%: YunNan BaiYao, WeiEr Pharmaceutical, TongCe Medical, DongFuLong, JingXin Pharmaceutical, EnHua Pharmaceutical, and HuaDong Pharmaceutical - 1 company expected to turn losses into profits: BeiJi ShenZhou-U [7][8] Sector Analysis - The report highlights significant growth in the CXO, innovative drug, and high-value consumables sectors for 2025, driven by favorable conditions in the global innovative drug industry, increased order signing, and rising investment sentiment in both domestic and international pharmaceutical markets [10][11] - The high-value consumables sector benefits from the recovery of domestic surgical demand and improved profit margins following stabilized procurement prices. Some traditional Chinese medicine companies have also exceeded market expectations [10][11] - In contrast, sectors such as IVD, raw materials, vaccines, and blood products are facing performance pressures [10][11] Investment Recommendations - The report continues to recommend focusing on the innovative drug and CXO sectors, with specific companies highlighted for attention: - CXO sector: WuXi AppTec, Kanglong Chemical, KaiLaiYing, HaoYuan Pharmaceutical, BaiAoSaiTu, Tigermed, NuoSiGe, ZhaoYan Pharmaceutical, YiNuoSi, and PuRuiSi - Innovative drug sector: HengRui Pharmaceutical, BeiJi ShenZhou-U, NuoCheng JianHua, AiDi Pharmaceutical, and WeiXing Biological [5][10]

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric (00042), Sinopec Oilfield Service (01033), and Zhejiang Shibao (01057) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Heng Rui Medicine (01276) are at the bottom of the list [1] Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 864.29% - Sinopec Oilfield Service (01033) with a premium rate of 361.80% - Zhejiang Shibao (01057) with a premium rate of 345.22% [1] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -14.10% - China Merchants Bank (03968) with a premium rate of -4.16% - Heng Rui Medicine (01276) with a premium rate of 0.99% [1] Deviation Value Rankings - The top three AH shares by deviation value are: - Sinopec Oilfield Service (01033) with a deviation value of 89.71% - Northeast Electric (00042) with a deviation value of 34.53% - Zhongwei New Materials (02579) with a deviation value of 25.28% [1] - The bottom three AH shares by deviation value are: - Zhejiang Shibao (01057) with a deviation value of -53.92% - Changfei Optical Fiber (06869) with a deviation value of -35.50% - Nanhua Futures (02691) with a deviation value of -30.81% [1] Additional Insights - The report includes detailed tables showing the premium rates and deviation values for various AH shares, indicating significant disparities in market valuations between H-shares and A-shares [2]

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

Core Insights - The report highlights the dominance of WuXi AppTec in the Chinese CRO market, holding nearly a quarter of the market share with a revenue of 29 billion yuan, significantly surpassing competitors like Kanglong Chemical and Tigermed [1] Group 1: Company Overview - WuXi AppTec was founded in 2000 in Wuxi, starting with basic chemical synthesis services and went public on the NYSE in 2007, marking its international expansion [3] - The company has integrated the entire industry chain from preclinical to commercialization through self-built production bases and cross-border acquisitions, becoming the absolute leader in China's CRO industry [3] Group 2: Revenue Growth - WuXi AppTec's revenue surged from 16.535 billion yuan in 2020 to 39.355 billion yuan in 2022, more than doubling in three years, with a continued high growth rate [6] - In 2023, the revenue exceeded 40 billion yuan, although a slight decline was observed in 2023-2024 due to the exit from COVID-19 commercialization projects, with revenues of 40.341 billion yuan and 39.241 billion yuan respectively [6] Group 3: Business Strategy - In 2024, WuXi AppTec's business layout is primarily focused on chemical services, generating 29.05 billion yuan, accounting for 74% of total revenue, with TIDES business revenue increasing by 70.1% to 5.8 billion yuan [8] - The company has a pipeline of 3,377 molecules, with laboratory analysis contributing 3.86 billion yuan and clinical CRO/SMO income at 1.81 billion yuan [8] Group 4: Global Positioning - WuXi AppTec is not only the leader in China's CRO industry but also ranks among the top globally, possessing significant international market influence [10] - The company aims to strengthen its global competitiveness by focusing on high-growth sectors like TIDES and CGT, while reducing non-core business activities [10]

Core Insights - The visit of UK Prime Minister Keir Starmer to China in January 2026 resulted in 11 positive outcomes, marking a new phase in UK-China relations characterized by "re-engagement" and "divergence management" [1] - China's direct investment in the UK has shifted from "capital scale expansion" to "high-quality supply chain integration" over the past five years, with a significant rebound in investment flow expected in 2024-2025, driven by strong performance in renewable energy and greenfield projects [1][4] - The establishment of a "High-Level Climate and Nature Partnership" during the visit validates the business logic of collaboration in the "net-zero emissions" sector, highlighting the complementary strengths of both countries [1][3] Investment Trends - China's direct investment in the UK has transitioned from acquisition-driven capital to strategic greenfield projects, with FDI stock declining from approximately £6 billion in 2020 to £3.7 billion by the end of 2023, representing about 0.2% of the UK's total inward FDI [5][6] - Despite the decline in FDI stock, the number of Chinese projects in the UK has remained robust, averaging 37 to 46 new projects annually from 2021 to 2025, with a notable rebound in investment flow expected to reach €10 billion in 2024-2025 [5][6] Employment Impact - Chinese enterprises in the UK employ over 57,000 individuals and generate nearly £99 billion in annual revenue, with at least 9,356 new jobs created from 2021 to 2025, peaking at 2,814 new jobs in the 2023 fiscal year [6] Regional Investment Distribution - Investment from China has shifted from a concentration in London to a more balanced distribution across the UK, with greenfield investments rising to 60% of total investments by 2025, benefiting regions such as the West Midlands and North East England [8][11] Strategic Focus Areas - The focus of Chinese investment has moved towards renewable energy and electric vehicle supply chains, with significant investments in offshore wind, energy storage, and battery technology [14][19] - The West Midlands has become a key area for electric vehicle supply chains, while the North East and Yorkshire are transitioning from traditional heavy industries to low-carbon manufacturing [15][19] Challenges and Opportunities - The UK faces increasing competition from other European countries for Chinese investment, with regulatory uncertainties and unclear review processes diminishing its attractiveness [20][21] - The UK's National Security and Investment Act (NSIA) presents challenges for Chinese enterprises, as the unpredictability of the review process can lead to increased costs and project delays [23][24] Recommendations for Improvement - To enhance its attractiveness to Chinese investors, the UK should establish a green investment fast track for low-sensitivity projects and create a standardized trust framework to help Chinese enterprises navigate the regulatory landscape [28][29] - Strengthening post-investment support systems and ensuring clear communication regarding project delivery processes will be crucial for fostering a conducive investment environment [31]

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...

Macro and Strategy Research - The US economy is expected to maintain resilience due to Trump's tax cuts and tech capital expenditures, with the Fed likely to keep interest rates unchanged amid mixed signals on employment and inflation [2] - The Eurozone is experiencing weak recovery, with uncertainties stemming from geopolitical issues, particularly related to Greenland, which may affect economic stability [2] Domestic Economy - China's GDP growth in Q4 2025 slowed due to high base effects, but overall growth targets were met, with a stronger supply than demand and external demand outpacing internal demand [3] - High-frequency data suggests that exports may remain strong in early 2026, supported by tax policy adjustments and semiconductor industry performance, while domestic consumption faces challenges [3] - Investment is expected to gradually recover, driven by manufacturing and infrastructure investments, although the real estate sector remains cautious [3] Domestic Policy Environment - The People's Bank of China announced a package of structural monetary policies, indicating potential for further rate cuts and reserve requirement ratio reductions [3] - Fiscal policies, including interest subsidies and risk-sharing measures, are aimed at stimulating economic activity and improving corporate financing willingness [4] Fixed Income Research - The bond market has shown a strong oscillation, with the central bank injecting over 9 trillion yuan into the market, and MLF operations reaching 900 billion yuan [6] - The issuance of local government bonds has lengthened in duration, reflecting strategies to take advantage of low interest rates [6] - The bond market is expected to continue its oscillation, with inflation and monetary policy being key factors influencing market dynamics [7] Industry Research - The pharmaceutical industry is witnessing significant collaborations, such as the strategic partnership between CSPC Pharmaceutical and AstraZeneca for innovative long-acting peptide drug development [8] - The SW Pharmaceutical sector index shows a TTM P/E ratio of 51.60, with a valuation premium of 259% over the CSI 300 index [9] - Investment opportunities are identified in innovative drugs, CXO, and upstream life sciences, with a focus on AI applications in healthcare and pharmaceuticals [9]

Group 1: Technology and AI - Alphabet (GOOGL US) is expected to maintain good visibility in its advertising business due to the gradual release of its valuation under pressure from AI search, with a projected cloud business growth rate of over 30% for the year [1] - Alibaba (BABA US) is anticipated to see a cloud business growth rate of 28%-30%, driven by strong demand in China, with significant contributions from its instant retail segment [1] - NVIDIA (NVDA US) is projected to achieve revenue exceeding 500 billion, with strong growth expected from its GB300 product line, which constitutes two-thirds of the Blackwell series [1] Group 2: E-commerce and Internet Services - Tencent (700 HK) is recommended as a top pick due to its strong investment in AI and steady growth in its core gaming and advertising businesses, with a target price of 700 [1] - Tencent Music (TME US) is expected to maintain a stable growth trajectory with a focus on subscription and non-subscription revenue streams, despite some margin pressure from new business initiatives [1] - Kuaishou (1024 HK) is projected to see significant revenue growth driven by its AI-enhanced content ecosystem, with a target price of 93 [2] Group 3: Healthcare and Pharmaceuticals - New Oxygen (SY US) is positioned well in the light medical beauty sector, with plans to expand its self-operated stores significantly by 2025, supported by a strong marketing capability and low customer acquisition costs [2] - Hansoh Pharmaceutical (3692 HK) is focusing on expanding its pipeline in oncology and other major indications, with a strong emphasis on innovative drug development [3] - BeiGene (6160 HK) is expected to exceed management's revenue guidance for 2025, driven by strong sales of its BTK inhibitor, with a projected peak sales potential of over 8 billion [4] Group 4: Energy and Materials - Saudi Aramco (ARAMCO AB) is positioned as a central player in global energy supply, with ongoing investments in hydrogen and carbon capture technologies, enhancing its long-term growth prospects [6] - MP Materials (MP US) is the only company in the U.S. with a fully scaled rare earth supply chain, benefiting from strong demand in the defense and renewable energy sectors [6] - Howmet Aerospace (HWM US) is expected to maintain a strong market position in gas turbine components, with a long order backlog supporting stable revenue growth [5]